MCO-010 Phase 2b Data Supports BLA Submission for Retinitis Pigmentosa
The Phase 2b RESTORE trial (NCT04945772) evaluating MCO-010 (sonpiretigene isteparvovec; Nanoscope Therapeutics) in patients with retinitis pigmentosa (RP) met its primary and secondary endpoints, significantly improving best-corrected visual acuity (BCVA) …